FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity
DAIC
MARCH 8, 2024
Food and Drug Administration ( FDA ) has approved an additional indication for Wegovy ( semaglutide ) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.
111 
Let's personalize your content